.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA04_Dalbavancin.Dalbavancin

Information

Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity primarily against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and is administered as an intravenous infusion.

Pharmacokinetics

Pharmacokinetic parameters are based on data from healthy adult volunteers receiving intravenous dalbavancin. Most studies use a two-compartment model.

References

1. Carrothers, TJ, et al., & Critchley, I (2020). Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. Clinical pharmacology in drug development 9(1) 21–31. DOI:10.1002/cpdd.695 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31087630

2. Turner, NA, et al., & Holland, TL (2022). Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials 23(1) 407–None. DOI:10.1186/s13063-022-06370-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35578360

3. Colaneri, M, et al., & Seminari, E (2024). Optimizing Antibiotic Therapy for Intravenous Drug Users: A Narrative Review Unraveling Pharmacokinetics/Pharmacodynamics Challenges. European journal of drug metabolism and pharmacokinetics 49(2) 123–129. DOI:10.1007/s13318-024-00882-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38332425

Revisions

• 06/2025 initial generated model